Table 1.
Patient baseline characteristics
| Characteristic | L-AMB (N = 237) | Placebo (N = 118) | P valuea |
|---|---|---|---|
| Age (years), median (IQR) | 45 (32–57) | 47 (28–60) | 0.82 |
| Male, n (%) | 139 (59) | 60 (51) | 0.16 |
| White, n (%) | 211 (89) | 100 (85) | 0.25 |
| Weight (kg), median (IQR) | 74.0 (66.0–84.0) | 74.7 (62.3–87.9) | 0.92 |
| Height (cm), median (IQR) | 170.0 (164.0–178.0) | 170.0 (164.0–179.0) | 0.94 |
| BMI (kg/m2), median (IQR) | 25.2 (22.7–28.7) | 25.0 (22.0–28.7) | 0.76 |
| Baseline ANC (cells/μL), median (IQR) | 820 (270–1880) | 560 (210–1610) | 0.27 |
| Patient ANC distribution, n (%) | |||
| <200 cells/μL | 49 (21.2) | 26 (22.8) | |
| 200 to < 500 cells/μL | 34 (14.7) | 28 (24.6) | |
| 500 to < 1500 cells/μL | 79 (34.2) | 26 (22.8) | |
| ≥1500 cells/μL | 69 (29.9) | 34 (29.8) | |
| Median days between start of remission induction and first dose of study drug (IQR) | 3 (2–4) | 3 (2–4) | 0.55 |
ANC, absolute neutrophil count.
a
Cochran–Mantel–Haenszel test for categorical variables and Wilcoxon rank-sum test for continuous variables.